{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:42:16Z","timestamp":1790246536680,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":3932,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1111\/j.1538-7836.2011.04602.x","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T08:31:32Z","timestamp":1325838692000},"page":"327-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?"],"prefix":"10.1016","volume":"10","author":[{"given":"M.","family":"CATTANEO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0010","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","article-title":"The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug\u2010induced defects","volume":"117","author":"Cattaneo","year":"2011","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y(12) inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on\u2010treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0025","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1538-7836.2007.02498.x","article-title":"Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection","volume":"1","author":"Cattaneo","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0030","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/nm.2469","article-title":"Paraoxonase\u20101 and clopidogrel efficacy \u2013 reply","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase\u20101 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCINTERVENTIONS.111.963025","article-title":"CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post\u2010myocardial infarction patients","volume":"4","author":"Hulot","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0045","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/nm.2386","article-title":"Paraoxonase\u20101 and clopidogrel efficacy","volume":"17","author":"Camps","year":"2011","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0050","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nm.2436","article-title":"Paraoxonase\u20101 and clopidogrel efficacy","volume":"17","author":"Dansette","year":"2011","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0055","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nm.2367","article-title":"Paraoxonase\u20101 and clopidogrel efficacy","volume":"17","author":"Cuisset","year":"2011","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0060","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2011.04409.x","article-title":"Relationship between paraoxonase\u20101 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study","volume":"9","author":"Fontana","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCGENETICS.111.960112","article-title":"Paraoxonase\u20101 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement","volume":"4","author":"Trenk","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0070","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase\u20101 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0075","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","article-title":"Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance","volume":"24","author":"Cattaneo","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0080","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on\u2010clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0085","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta\u2010analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0090","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","article-title":"Clopidogrel\u2010drug interactions","volume":"57","author":"Bates","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0095","article-title":"A Meta\u2010Analysis of Impact of Proton Pump Inhibitors on Antiplatelet Effect of Clopidogrel","author":"Chen","year":"2011","journal-title":"Cardiovasc Ther"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0100","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","article-title":"Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin","volume":"4","author":"Gilard","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0105","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double\u2010blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo\u2010controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0115","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0120","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FJC.0b013e3181f68209","article-title":"The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests","volume":"56","author":"Gremmel","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel\u2010treated patients according to cytochrome P450 2C19*2 loss\u2010of\u2010function allele or proton pump inhibitor coadministration: a systematic meta\u2010analysis","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0130","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta\u2010analysis","volume":"8","author":"Siller\u2010Matula","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0135","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0140","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0145","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton\u2010pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-152-6-201003160-00003","article-title":"Outcomes with concurrent use of clopidogrel and proton\u2010pump inhibitors: a cohort study","volume":"152","author":"Ray","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0155","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/CIRCULATIONAHA.109.873497","article-title":"Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome","volume":"120","author":"Rassen","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0160","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","volume":"123","author":"Simon","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0165","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/pds.2202","article-title":"Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome","volume":"20","author":"Hsiao","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0170","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0175","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ng749","article-title":"Replication validity of genetic association studies","volume":"29","author":"Ioannidis","year":"2001","journal-title":"Nat Genet"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0180","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced\u2010function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta\u2010analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/tpj.2010.21","article-title":"Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta\u2010analysis","volume":"11","author":"Sofi","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0190","doi-asserted-by":"crossref","first-page":"d4588","DOI":"10.1136\/bmj.d4588","article-title":"Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta\u2010analysis","volume":"343","author":"Bauer","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/hrt.2011.227652","article-title":"Meta\u2010analyses of the association between cytochrome CYP2C19 loss\u2010 and gain\u2010of\u2010function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel","volume":"98","author":"Zabalza","year":"2012","journal-title":"Heart"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0200","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta\u2010analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0205","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/447655a","article-title":"Replicating genotype\u2010phenotype associations","volume":"447","author":"Chanock","year":"2007","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0210","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0215","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON\u2010TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0220","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/107602960100700403","article-title":"The oral anticoagulant saga: past, present, and future","volume":"7","author":"Duxbury","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0225","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/CIRCULATIONAHA.109.904003","article-title":"Medication adherence in cardiovascular disease","volume":"121","author":"Baroletti","year":"2010","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1111\/j.1538-7836.2011.04602.x_bb0230","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low\u2010molecular\u2010weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"3","author":"Hirsh","year":"2004","journal-title":"Chest"},{"issue":"Suppl","key":"10.1111\/j.1538-7836.2011.04602.x_bb0235","doi-asserted-by":"crossref","first-page":"20A","DOI":"10.1016\/j.amjcard.2008.11.019","article-title":"Methods for the measurement of platelet function","volume":"3","author":"Michelson","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.acvd.2009.11.004","article-title":"Clopidogrel response: head\u2010to\u2010head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting","volume":"103","author":"Cuisset","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1160\/TH08-09-0577","article-title":"Comparison of methods to evaluate clopidogrel\u2010mediated platelet inhibition after percutaneous intervention with stent implantation","volume":"101","author":"Gremmel","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0250","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1538-7836.2007.02656.x","article-title":"Different methodologies for evaluating the effect of clopidogrel on platelet function in high\u2010risk coronary artery disease patients","volume":"5","author":"Paniccia","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0255","first-page":"287","article-title":"Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point\u2010of\u2010care tests on whole blood in high\u2010risk patients","volume":"104","author":"Paniccia","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0260","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0265","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1373\/clinchem.2009.137471","article-title":"Long\u2010term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention","volume":"56","author":"Madsen","year":"2010","journal-title":"Clin Chem"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MBC.0b013e328332dbd4","article-title":"Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator\u2010Stimulated Phosphoprotein flow cytometry","volume":"21","author":"von Beckerath","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0275","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","article-title":"Correlation between Light Transmission Aggregometry, VerifyNow P2Y12, and VASP\u2010P Platelet Reactivity Assays Following Percutaneous Coronary Intervention","volume":"24","author":"Gaglia","year":"2011","journal-title":"J Interv Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0280","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0285","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0290","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","article-title":"Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial","volume":"121","author":"Pocock","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0295","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","article-title":"Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel\u2010treated patients: initial evidence of a therapeutic window","volume":"56","author":"Sibbing","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0300","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1538-7836.2009.03458.x","article-title":"Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH","volume":"7","author":"Cattaneo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0305","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1309\/AJCP9V3RRVNZMKDS","article-title":"Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry","volume":"134","author":"Hayward","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0310","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/09537104.2010.499483","article-title":"Intra\u2010individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy","volume":"21","author":"Arm\u00e9ro","year":"2010","journal-title":"Platelets"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1160\/TH10-07-0440","article-title":"Stability of the high on\u2010treatment platelet reactivity phenotype over time in clopidogrel\u2010treated patients","volume":"105","author":"Jaitner","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0320","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcin.2008.09.004","article-title":"Clopidogrel 150\u2003mg\/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP\u201002 (Vasodilator\u2010Stimulated Phosphoprotein\u201002) randomized study","volume":"1","author":"Aleil","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0325","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJM198706113162405","article-title":"Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death","volume":"316","author":"Tofler","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0330","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/09537104.2011.582900","article-title":"Diurnal variation in platelet inhibition by clopidogrel","volume":"22","author":"Kozinski","year":"2011","journal-title":"Platelets"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0335","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator\u2010stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0345","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1161\/CIRCULATIONAHA.108.857722","article-title":"Can we override clopidogrel resistance?","volume":"119","author":"Pena","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0350","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0355","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0360","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard\u2010 vs high\u2010dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0365","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.2011.332","article-title":"An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial","volume":"305","author":"Gurbel","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0370","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","volume":"56","author":"Campo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0375","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time\u2010dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial","volume":"124","author":"Price","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0380","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long\u2010term cardiovascular events among patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0385","unstructured":"FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm190836.htm; accessed 3 August 2010."},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0390","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2165\/11535830-000000000-00000","article-title":"Comparative effectiveness research and personalized medicine: catalyzing or colliding?","volume":"28","author":"Epstein","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0395","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss\u2010of\u2010function polymorphism and of major demographic characteristics on residual platelet function after loading an maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0400","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0405","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/hrt.2010.220509","article-title":"Variability in on\u2010treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting","volume":"97","author":"Bouman","year":"2011","journal-title":"Heart"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0410","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1538-7836.2009.03554.x","article-title":"CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring","volume":"7","author":"Aleil","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0415","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON\u2010TIMI 38 trial","volume":"30","author":"Michelson","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0420","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on\u2010treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04602.x_bb0425","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2011.04602.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622061888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622061888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2011.04602.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:59:30Z","timestamp":1761533970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622061888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1538783622061888"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04602.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04602.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}